Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19129731 | 0.85 | GRIN2D (0.47) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL17707285 | 0.81 | SIGMAR1 (0.50) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL17707286 | 0.81 | SIGMAR1 (0.50) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL58461 | 0.81 | GABRA1 (0.50) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1435119 | 0.81 | GABRA1 (0.48) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7050106 | 0.75 | SIGMAR1 (0.49) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL19129733 | 0.75 | PLAU (0.47) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL18265417 | 0.74 | HTR3E (0.48) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL16961786 | 0.74 | TP53 (0.42) | TP53IDO1 | |
| SCHEMBL6995828 | 0.74 | SIGMAR1 (0.47) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017463-B2 | Inhibitors of deubiquitinating proteases | BRANDEIS UNIVERSITY (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170204055-A1 | INHIBITORS OF DEUBIQUITINATING PROTEASES | BRANDEIS UNIVERSITY (US) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017463-B2 | Inhibitors of deubiquitinating proteases | USP1, USP2, USP18 | SIGMAR1 4223/4885GRIN2D 4433/4885GRIN3B 3871/4885 |
| US-20170204055-A1 | INHIBITORS OF DEUBIQUITINATING PROTEASES | USP1, USP2, USP18 | SIGMAR1 4223/4885GRIN2D 4433/4885GRIN3B 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.